Unlock this StockReport nowClick to Unlock

Verona Pharma Share News

VRP 57.5p -1.0  -1.7%
9:27am 2.00k
StockRank



4th Jun BRIEF-Verona Pharma Initiates Phase 2 Trial With Dose Inhaler Formulation Of Ensifentrine
4th Jun Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
4th Jun Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
30th May Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
30th May Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
29th May Verona Pharma PLC - PDMR Dealing
20th May Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
20th May Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
7th May Result of AGM
7th May BRIEF-Verona Pharma Initiates Additional Phase 2B Clinical Trial With Nebulized Ensifentrine To Inform Dose Selection For Phase 3 Trials
7th May Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
7th May Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
7th May Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
7th May Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
2nd May Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
2nd May Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
1st May Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
1st May Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
1st May Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
1st May Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker


Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis